Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00080
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
Cot-APTEDB-SN38
|
|||||
| PDC Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Tumor
|
|||||
| Peptide Name |
Cot-APTEDB
|
Peptide Info | ||||
| Receptor Name |
Vesicle-associated membrane protein 8 (VAMP8)
|
Receptor Info | ||||
| Drug Name |
7-Ethyl-10-hydroxycamptothecin
|
Drug Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Ester bond
|
Linker Info | ||||
| Peptide Modified Type |
Chemically synthesize
|
|||||
Full List of Activity Data of This Peptide-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Anti-tumor activity |
23.90%
|
|||
| Administration Time | 6 days | ||||
| Administration Dosage | Equivalent to 2 mg SN38/kg | ||||
| Description |
In situ HC[cot-APTEDB-SN38/Abcot] at an SN38/kg dose-equivalent of 2 mg effectively suppressed tumor growth and showed much greater antitumor activity (49.8% inhibition) than both cot-APTEDB-SN38 alone (23.9% inhibition) and CPT-11 (10.6% inhibition).
|
||||
| In Vivo Model | EDB-positive human glioblastoma-bearing mice. | ||||
| Half life period | 2.01 h | ||||
References